{"name":"Azura Ophthalmics","slug":"azura-ophthalmics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOMzNZUWplUkhuR3lmYnZibFhXcGsybFlsdzdsVEpQaHlLbFB0dV9IQXNQMWJrVEt2MktTUHJIYzhGVWQ3aEE0eG1HVHJrSHlEcVltWDRmSmFSNzVJMHc4V0xNSVY2bU9iQkRYTXpGVEhtVjU1dmNJS2xuYks5cm5MZURpMC1fQkRCQ1BVeFEzSlhQeGN3LW5pT19QYkpuNE04emZ3NE5hXzhhX3liUnI3emtwckROMWZfYXpia3g5c1pqY05NcW9qTXFmWlRPNTFzSEtZ?oc=5","date":"2025-12-10","type":"pipeline","source":"Business Wire","summary":"Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026 - Business Wire","headline":"Azura Ophthalmics Corporate Update: AZR-MD-001 NDA Submission Expected in 2H 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQWTM4Wm52OUFTcGlJdXoxQWJaS0ZWTnJnNFc0RTQxUnhQNmtRekdoRGFXdW8zUDBlNU5hclVyYzlXWlNGWHN4RTdEWjNLWU9POWhtX19LNVpXMGRwUko1aDh0OW41RWhVVlJTbnVZZnM0N0tneE5LNDR5d0xWUzA1Ml9GT0NOcmsyV1NCbzZ1M3lzY3lERThBclV0aEM1V3FFank1QmpMdXBhZnJOOFE?oc=5","date":"2025-07-21","type":"pipeline","source":"Fierce Pharma","summary":"Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda - Fierce Pharma","headline":"Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPTVdOQ2ZxWVFjRnJ5ZWVTOG4zZFBETFJxMUVGYWQwb1pORTZGWjVGa29YT1MzOHpkYWZPazFUdzgxdE1yb3RrQm43blYtbUtVMEg5dUlHU3BUYlBZS0NLUVBINDdNckJkaDJlNHhxeXhOa0RVWjhCVndXR0JFWGhaZ2Q1Z25KOXhiREw4blRVWmpzTUhoZmtLRV8xWFVPUGw3WVhqS2NkVkx2MVEta1hxaE1wRkJaN3VjLWI2WWJ2VDFBTDlnajdwVlNNUnptOXh2eUdEN29lcGZPR2sxZjZPODdTOF9yVUx0ZnpzVVl5aEo5TkNDbWppRA?oc=5","date":"2025-02-06","type":"pipeline","source":"BioSpace","summary":"Meibomian Gland Dysfunction Market Size to Reach USD 4.9 Billion by 2035, Impelled by Increasing Prevalence of Dry Eye Disease - BioSpace","headline":"Meibomian Gland Dysfunction Market Size to Reach USD 4.9 Billion by 2035, Impelled by Increasing Prevalence of Dry Eye D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOaG5VSkoxbjdqNWVLTzUwLV9lMllBZ000TUhuU2c4SVk5MzBDbkNEaXdvQU1vSXRaTXNCNDhPX0NzTzY5Z1QwckNxZWttbXF0cHpQNU45bk9UUUdtLXBKVk95WEg2NGZrMjVsdS1fSGlSaHdEOGhKckhJNm5GcmZNX0N1dHVxYnVXRHZCZHkzc2NxeEhFdVFvbFp3NEVIVEo0QUtuN2thMzlYNVduM2VzZEJNcjZhM1pOSUd2cW5PQWNfMUVkcGZaMy03dmlFVTlVT0dJ?oc=5","date":"2024-06-07","type":"trial","source":"Optometry Times","summary":"Azura Ophthalmics enrolls first patient in Phase 3 clinical trial for AZR-MD-001 in patients with MGD - Optometry Times","headline":"Azura Ophthalmics enrolls first patient in Phase 3 clinical trial for AZR-MD-001 in patients with MGD","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNcklqSFpydHRORFo4WnJTd1FzNU91NkRXYjhoZ0ctYmgzQmJ5QkJiV2Q1a2x3aTN1cGdRSnRZc2VnbTBQTENScWJuU2VRV1gtSFk4V2M2aVM4aTBKbHNsWWd6c284Wm1uWVI0VlJkbkc3NEhsZzk3Ym5hUkpybEQwdXBTdnpjUGd4OEkwMzlKbU9IU0k?oc=5","date":"2024-01-08","type":"pipeline","source":"insightnews.com.au","summary":"Positive results for Azura Ophthalmics investigational dry eye therapy - insightnews.com.au","headline":"Positive results for Azura Ophthalmics investigational dry eye therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMnlnRVl3R0lNZjNzd3pqdE0yUkZQTVlFQUdzYl9UU0wtaHpscW5yTmVQdl9GWTk4RE1CVkR3b19CdUdicXpmbnBhVXdiaEVEWGM1M2NQWFFSbjVDUzRDNjU2WWVTcFpBdXRPN0xxRGM2ZmdpRUFfQmNURThkZXVWaEVNeUxrQzQ3WHplVUVKTGFFWnJ2Yjl3eHZ1Ry1xaWV4Zlg5WTdTdnZlZ0F2OGhJeERxbU15R25vby1HWHY2MmwxS052aXRINjlVM2JGSjB6Z0NaT2JxeDAzT19BNnB1a2ZBWHlsVkd0cFlfTHJlSi1oY3BKdEtTUXVVTQ?oc=5","date":"2023-12-18","type":"trial","source":"Ophthalmology Times","summary":"Azura Ophthalmics announces positive results from Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort - Ophthalmology Times","headline":"Azura Ophthalmics announces positive results from Phase 2 clinical trial of AZR-MD-001 in patients with contact lens dis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE01OFFySmhjR19uNnJjNVROMWxsZjkwMUh6OS1ad3F4MHVaYkZsQWUtVGJFVmZVWUw2RHFLYTVVU2h5a2J0V1VyeWdRWktQR0k3TV8yWEJ0aEUtSnRmNGZHTnRHeHhGbFI5U0hlR3JwSkwwMlZWbjZ4ekdB?oc=5","date":"2023-06-01","type":"pipeline","source":"Labiotech.eu","summary":"Five ophthalmology biotech companies to look out for - Labiotech.eu","headline":"Five ophthalmology biotech companies to look out for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQRTFzOTBSalhGWlFoUUJSb0dELUxEajdXN3RqWkJPT01xQVpJN0JfbE12eGNjbEttdHZGbnZYUjVpTDR0Zm9EMzdwZUF3c3B1SW5lT2lEWVhPSVBjdmFkdmhna1hSb1N6UVllWTJJU015WkhoMGo4ei1sNlE3eTdYeA?oc=5","date":"2021-10-01","type":"pipeline","source":"insightnews.com.au","summary":"Ikervis ciclosporin eye drop now PBS-listed - insightnews.com.au","headline":"Ikervis ciclosporin eye drop now PBS-listed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1lZG9qZTdxRV8yLWpIX0g2UWIxLVFSdm9obVo0bDN1Zy03NkFsUEZKcWVkWW5rSEp6Ync5NWl1alYwckk5cmN5bFZRSEozdGZUVFdiRw?oc=5","date":"2021-03-04","type":"pipeline","source":"pharmaphorum","summary":"Two biotechs target dry eye disease after Novartis' Xiidra problems - pharmaphorum","headline":"Two biotechs target dry eye disease after Novartis' Xiidra problems","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPampqU044amlLRmNhUzlYWUhZcnpuMnBYVHJ2NHFjVzRveVQzTlBxVkV2azZ6YmF3c1dRb1hfeWltNURDbmFfdndnVGZLZHJZU2p2SHRzZlhTdEtrb0VzQlItZFVmV0xoSy0yaUlCZzRodDhPM3R6dk00U2U5YWlsMUVxY2p2TUtXN2YzemZLQjdHYWFpd3hjb3FBdE1zNE5iRDZGc3diMWhsaVhET203bVR4bGdpVFdfT1g5emMtTXRFeFV6alZfaDdJR0xZUQ?oc=5","date":"2017-10-17","type":"pipeline","source":"AFR","summary":"Azura Opthalmics raises $20m from Brandon Capital, others for dry eye cure - AFR","headline":"Azura Opthalmics raises $20m from Brandon Capital, others for dry eye cure","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}